Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 121 - 130 of 243
Alternative Name: Levonorgestrel Gastric Resident Dosage Form, Levonorgestrel Gastric Retentive Dosage Form
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Lyndra Therapeutics, Massachusetts Institute of Technology
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Levonorgestrel (LNG) Intracervical Device (ICD)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Vaginal, Other
Developer: University of Helsinki, Population Council
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Levonorgestrel (LNG)-only patch; AG890
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Agile Therapeutics
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: One-year LNG Single Rod Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: CONRAD, FEI Technologies
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable, Subdermal
Developer: Orbis Biosciences
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: FHI 360
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: (3β,13ξ)-Lup-20(29)-en-3-ol; Clerodol; Monogynol B; Fagarasterol; Farganasterol
User: Female, Male
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Oral, Other
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Merck
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Emergency
Delivery Method: Oral
Developer: CONRAD
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Delivery Method: Vaginal Ring
Developer: Andromaco
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 41 - 50 of 70
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Merck
Development Stage: Prototype Development
Alternative Name: Metalloprotease
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University
Development Stage: Target Validation
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Microchips Biotech, Inc.
Development Stage: Prototype Development
Target
User: Male
Hormonal: No
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Target Validation
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Washington University
Development Stage: Compound ID/Selection
Alternative Name: Lavax Vaginal Suppository
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Developer: Lavax
Development Stage: Lead Optimization
User: Male
Hormonal: No
Delivery Method: Oral
Developer: North Shore University Hospital in New York
Development Stage: Lead Optimization
Alternative Name: Nomegestrol acetate (NOMAC) vaginal ring
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Developer: Merck
Development Stage: Prototype Development
User: Female, Male
Duration Type: Short-acting, Pericoital
Delivery Method: Injectable, Vaginal, Other, Other
Development Stage: Lead Optimization
User: Male
Hormonal: Yes
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Lead Optimization

Pages

Displaying 101 - 110 of 121
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR)
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: FHI 360
Development Stage: Phase I
Alternative Name: Hormonal Intrauterine Ball
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: OCON Medical Ltd.
Development Stage: Pre-clinical
Alternative Name: NSP-989; NSP-989 COMBO; Tanaproget COMBO; WAY-166989
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Ligand Pharmaceuticals, Inc.
Development Stage: Phase II
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Alternative Name: Tenofovir Disoproxil Fumarate (TDF) + Levonorgestrel Vaginal Ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Albert Einstein College of Medicine, NIAID, Northwestern University
Development Stage: Phase I
Alternative Name: Testicular heat supplementation
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Testicular
Developer: University of California at Los Angeles
Development Stage: Phase II
User: Male
Hormonal: No
Duration Type: Permanent, Short-acting
Delivery Method: Testicular
Developer: Parsemus Foundation, University of Bari, University of California, University of North Carolina at Chapel Hill
Development Stage: Pre-clinical
Alternative Name: TU; Aveed
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Bayer HealthCare, National Research Institute for Family Planning in Beijing
Development Stage: Phase III
Alternative Name: TV-46046
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Teva Branded Pharmaceutical Products R&D, Inc.
Development Stage: Phase I

Pages

Displaying 51 - 52 of 52
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed

Pages

CSV